Trudy M. Forte

Lypro Biosciences Inc. operates as a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitates targeting to specific receptor. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancer such as mantle cell lymphoma. The company was founded by Michael Oda, Murray P Brozinsky and Robert O. Ryan in 2004 and is headquartered in Berkeley, CA.

Lypro Biosciences Inc. operates as a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitates targeting to specific receptor. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancer such as mantle cell lymphoma. The company was founded by Michael Oda, Murray P Brozinsky and Robert O. Ryan in 2004 and is headquartered in Berkeley, CA.

Lypro Biosciences Inc. operates as a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitates targeting to specific receptor. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancer such as mantle cell lymphoma. The company was founded by Michael Oda, Murray P Brozinsky and Robert O. Ryan in 2004 and is headquartered in Berkeley, CA.

Lypro Biosciences Inc. operates as a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitates targeting to specific receptor. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancer such as mantle cell lymphoma. The company was founded by Michael Oda, Murray P Brozinsky and Robert O. Ryan in 2004 and is headquartered in Berkeley, CA.

Lypro Biosciences Inc. operates as a therapeutic development company whose proprietary drug delivery nanotechnology increases the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitates targeting to specific receptor. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancer such as mantle cell lymphoma. The company was founded by Michael Oda, Murray P Brozinsky and Robert O. Ryan in 2004 and is headquartered in Berkeley, CA.